CELZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CELZ is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has short-term positive momentum and an encouraging analyst catalyst, but the overall technical setup is still weak, there is no strong proprietary buy signal, and the company remains unprofitable with deteriorating EPS. For an impatient investor, this is not a clean entry; hold and wait for stronger confirmation.
CELZ closed at 2.37, up from 2.29, showing mild near-term strength. However, the MACD histogram is still below zero, the RSI at 61.2 is neutral, and the moving averages remain bearish with SMA_200 > SMA_20 > SMA_5. That indicates the broader trend is still not fully reversed. Price is trading just above pivot 2.241 and below R1 2.364? Actually it closed slightly above R1, which is constructive, but the lack of trend confirmation makes this a weak technical buy. The stock trend model suggests upside over 1 week to 1 month, but not enough to outweigh the broader setup.
Roth Capital reiterated a Buy rating and raised attention on highly positive pilot study results for Ultrasome in osteoarthritis of the knee, including 93% of patients showing clinically meaningful improvement in mobility and pain reduction without serious adverse events. This is a meaningful event-driven catalyst and could support sentiment if follow-up data or broader development progress continues.
No news in the recent week, so there is no active near-term momentum from fresh company updates beyond the analyst commentary. Hedge funds and insiders are both neutral with no significant recent trading trends. Financials remain weak with negative net income and negative EPS, and gross margin is still deeply negative. There is no congress trading data and no politician or influential figure trading activity reported.
Latest quarter reported was 2025/Q4. Revenue was 3,000, flat year over year, which shows no growth. Net income was -1,887,674, still a large loss, though slightly improved year over year. EPS fell to -0.7, down 35.78% YoY, which is a negative sign. Gross margin remained deeply negative at -964.77, despite some improvement. Overall, the latest quarter does not show healthy operating momentum.
Recent analyst sentiment is positive but limited: Roth Capital’s Jonathan Aschoff called the Ultrasome pilot data highly positive and maintained a Buy rating with a $20 price target, far above the current price near $2.37. That is a strong bullish target, but it is based on early clinical evidence rather than proven commercial execution. Wall Street pros currently see the upside potential as large, but the bear case remains the company’s lack of profitability, very small revenue base, and dependence on development-stage catalysts.
